The 37 references in paper A. Mazurov V., V. Spiridonova A., А. Мазуров В., В. Спиридонова А. (2017) “АПТАМЕРЫ — НОВЫЕ ФАРМАКОЛОГИЧЕСКИЕ СУБСТАНЦИИ ДЛЯ АНТИКОАГУЛЯНТОВ // APTAMERS ARE NEW PHARMACOLOGICAL SUBSTANCES FOR THE DEVELOPMENT OF ANTICOAGULANTS” / spz:neicon:aterotromboz:y:2017:i:1:p:134-144

1
Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov, 2010, 9: 537-550.
(check this in PDF content)
2
Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem, 2011, 18: 4206–4214.
(check this in PDF content)
3
Kadioglu O, Malczyk AH, Greten HJ, Efferth T. Aptamers as a novel tool for diagnostics and therapy. Invest New Drugs, 2015, DOI 10.1007/s10637015-0213-y.
(check this in PDF content)
4
Li W, Wang K, Zhao M, Yang X, Chen M, Lan X. Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: current status. Thromb Res, 2014, 134: 769–773.
(check this in PDF content)
5
Мазуров А.В. Физиология и патология тромбоцитов. М.: Литтерра, 2011: 79-84.
(check this in PDF content)
6
Cosmi B. ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. Curr Opin Mol. Ther., 2009, 11: 322-328.
(check this in PDF content)
7
Diener JL, Daniel LagassО, HA, Duerschmied D, Merhi Y, Tanguay JF, Hutabarat R, Gilbert J, Wagner DD, Schaub R. Inhibition of von Willebrand factor mediated platelet activation and thrombosis by the anti von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost, 2009, 7: 1155-1162.
(check this in PDF content)
8
Arzamendi D, Dandachli F, ThОorРt JF, Ducrocq G, Chan M, Mourad W, Gilbert JC, Schaub RG, Tanguay JF, Merhi Y. An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis. Clin Appl Thromb Hemost, 2011: 17, E70-E78.
(check this in PDF content)
9
Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG. Firstin-human evaluation of anti–von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation, 2007, 116: 2678-2686.
(check this in PDF content)
10
Tsai H-M. Thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. In: Platelets. Third Edition. (ed. Michelson AD). Amsterdam, Boston, Heidelberg et al: Academic Press, Elsevier Inc. 2013. pp. 883-908.
(check this in PDF content)
11
Мазуров А.В. Физиология и патология тромбоцитов. М.: Литтерра, 2011: 291-301.
(check this in PDF content)
12
Cataland SR, Peyvandi F, Mannucci PM, Lammle B, Kremer Hovinga JA, Machin SJ, Scully M, Rock G, Gilbert JC, Yang S, Wu H, Jilma B, Knoebl P. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol, 2012, 87: 430-432.
(check this in PDF content)
13
Jilma-Stohlawetz P, KnЪbl P, Gilbert JC, Jilma B. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost, 2012, 108: 284-290.
(check this in PDF content)
14
Markus HS, McCollum C, Imray C., Goulder MA, Gilbert J, King A. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke, 2011, 42: 2149-2153.
(check this in PDF content)
15
Smith SB, Gailani D. Update on the physiology and pathology of factor IX activation by factor XIa. Expert Rev Hematol, 2008, 1: 87–98.
(check this in PDF content)
16
Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, Alexander JH, Becker RC, Rusconi CP. First-inhuman experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation, 2006, 114: 2490-2497.
(check this in PDF content)
17
Rusconi CP1, Roberts JD, Pitoc GA, Nimjee SM, White RR, Quick G Jr, Scardino E, Fay WP, Sullenger BA. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnology,2004, 22: 14231428.
(check this in PDF content)
18
Nimjee SM, Keys JR, Pitoc GA, Quick G, Rusconi CP, Sullenger BA. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther, 2006, 14: 408415.
(check this in PDF content)
19
Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Alexander JH, Harrington RA, Tonkens RM, Becker RC, Rusconi CP. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation, 2008, 117: 2865-2874.
(check this in PDF content)
20
Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, Fry E, Chan MY, Tonkens RM, Zelenkofske S, Alexander JH, Harrington RA, Rusconi CP, Becker RC. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation, 2010, 122: 614-622.
(check this in PDF content)
21
Povsic TJ, Vavalle JP, Aberle LH, Kasprzak JD, Cohen MG, Mehran R, Bode C, Buller CE, Montalescot G, Cornel JH, Rynkiewicz A, Ring ME, Zeymer U, Natarajan M, Delarche N, Zelenkofske SL, Becker RC, Alexander JH, RADAR Investigators A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J, 2013, 34: 2481–2489
(check this in PDF content)
22
Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, Laanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ, Merkely B, Lopez-Sendon J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J, Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD, Hasselblad V, Becker RC, Alexander JH, REGULATEPCI Investigators. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet, 2016, 387: 349–356.
(check this in PDF content)
23
Ganson NJ, Povsic TJ, Sullenger BA, Alexander JH, Zelenkofske SL, Sailstad JM, Rusconi CP, Hershfield MS. Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol, 2016, 137: 1610-1613.
(check this in PDF content)
24
Povsic TJ, Lawrence MG, Lincoff AM, Mehran R, Rusconi CP, Zelenkofske SL, Huang Z, Sailstad J, Armstrong PW, Steg PG, Bode C, Becker RC, Alexander JH, Adkinson NF, Levinson AI, REGULATE-PCI Investigators. Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J. Allergy Clin Immunol., 2016, 138: 1712-1715.
(check this in PDF content)
25
Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood,2005, 106: 2605-2612.
(check this in PDF content)
26
Arsenault KA, Hirsh J, Whitlock RP, Eikelboom JW. Direct thrombin inhibitors in cardiovascular disease. Nat Rev Cardiol, 2012, 9: 402-414.
(check this in PDF content)
27
Bock LC. Griffin LC, Latham JA, Vermaas EH, Toole JJ. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 1992, 355: 564–566.
(check this in PDF content)
28
Macaya RF, Schultze P, Smith FW, Roe JA, Feigon J. Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Pro. Natl Acad Sci USA, 1993, 90: 3745–3749.
(check this in PDF content)
29
Padmanabhan K, Padmanabhan KP, Ferrara JD, Sadler JE, Tulinsky A. The structure of a-thrombin inhibited by a 15-mer single-stranded DNA aptamer. J Biol Chem, 1993, 268: 17651-17654.
(check this in PDF content)
30
Russo Krauss I, Spiridonova V, Pica A, Napolitano V, Sica F. Different duplex/quadruplex junctions determine the properties of anti-thrombin aptamers with mixed folding. Nucleic Acids Res, 2016, 44: 983–991.
(check this in PDF content)
31
Добровольский А.Б., Титаева Е.В., Хаспекова С.Г., Спиридонова В.А., Копылов А.М., Мазуров А.В. Ингибирование активности тромбина ДНК аптамерами. Бюлл. Эксп. Биол. Мед., 2009, 148: 41-45.
(check this in PDF content)
32
Griffin LC, Tidmarsh GF, Bock LC, Toole JJ, Laung LK. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood,1993, 81: 3271-3276.
(check this in PDF content)
33
DeAnda A Jr, Coutre SE, Moon MR, Vial CM, Griffin LC, Law VS, Komeda M, Leung LL, Miller DC. Pilot study of the efficacy of a thrombin inhibitor for yse during cardiopulmonary bypass. Ann Thorac Surg, 1994, 58: 344-350.
(check this in PDF content)
34
Cпиридонова В.А., Головин А.В., Копылов А.М., Добровольский А.Б., Мазуров А.В. Аптамерный олигонуклеотид — прямой ингибитор тромбина. Патент РФ No 2401306 Бюллетень изобретений. 2010 г. No28.
(check this in PDF content)
35
Мазуров А.В., Титаева Е.В., Хаспекова С.Г., Сторожилова А.Н., Спиридонова В.А., Копылов А.М., Добровольский А.Б. Свойства нового ДНК аптамера — прямого ингибитора тромбина. Бюлл Эксп Биол Мед, 2010, 150: 394-397.
(check this in PDF content)
36
Спиридонова В.А., Головин А.В., Копылов А.М., Добровольский А.Б., Мазуров А.В. Модифицированные ДНК аптамеры, ингибирующие активность тромбина. Патент РФ No2410432. Бюллетень изобретений. 2011 г. No3.
(check this in PDF content)
37
Добровольский А.Б., Спиридонова В.А., Мазуров А.В. Способ ингибирования тромбообразования и ускорения фибринолиза с помощью ДНК аптамеров, ингибирующих активность тромбина, в эксперименте. Патент РФ No 2559545. Бюлле-
(check this in PDF content)